Phase I Trial: Quotient Code QSC303299

Phase I Trial: Quotient Code QSC303299 [the full scientific title will be published within 30 months after the end of the trial]

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10840798

Enrollment

Registered

2026-02-06

Start date

2026-03-07

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. Other

Interventions

Eligibility

Sex/Gender

Male

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Exclusion criteria

Exclusion criteria: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Countries

England, United Kingdom

Contacts

Public ContactVicore Study Doctor

karin.eklund.vanderpol@vicorepharma.com+46 (0)317880560

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 19, 2026